Thierry Calandra

Summary

Affiliation: Centre Hospitalier Universitaire Vaudois
Country: Switzerland

Publications

  1. ncbi The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
    Malgorzata Mikulska
    Division of Infectious Diseases, San Martino University Hospital, L, go R, Benzi, 10, Genoa, Italy
    Crit Care 14:R222. 2010
  2. ncbi Pathogenesis of septic shock: implications for prevention and treatment
    T Calandra
    Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Chemother 13:173-80. 2001
  3. ncbi Macrophage migration inhibitory factor and host innate immune responses to microbes
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Scand J Infect Dis 35:573-6. 2003
  4. ncbi Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Infect Dis 187:S385-90. 2003
  5. ncbi Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Eur J Immunol 37:3509-21. 2007
  6. ncbi Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4)
    Thierry Roger
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Endotoxin Res 9:119-23. 2003
  7. ncbi Role of MyD88 and Toll-like receptors 2 and 4 in the sensing of Parachlamydia acanthamoebae
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Infect Immun 78:5195-201. 2010
  8. ncbi Macrophage migration inhibitory factor: a regulator of innate immunity
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Nat Rev Immunol 3:791-800. 2003
  9. ncbi Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Blood 117:1205-17. 2011
  10. ncbi Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection
    Julie Delaloye
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Cytokine 60:338-40. 2012

Detail Information

Publications61

  1. ncbi The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
    Malgorzata Mikulska
    Division of Infectious Diseases, San Martino University Hospital, L, go R, Benzi, 10, Genoa, Italy
    Crit Care 14:R222. 2010
    ..Mannan antigen (Mn) and anti-mannan antibodies (A-Mn) are present in patients with IC. On behalf of the Third European Conference on Infections in Leukemia, the performance of these tests was analysed and reviewed...
  2. ncbi Pathogenesis of septic shock: implications for prevention and treatment
    T Calandra
    Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Chemother 13:173-80. 2001
    ..The exciting results obtained recently with treatment strategies designed to correct coagulation abnormalities occurring during sepsis are an example of how research may ultimately translate into improved patient care...
  3. ncbi Macrophage migration inhibitory factor and host innate immune responses to microbes
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Scand J Infect Dis 35:573-6. 2003
    ..Given that it is a pivotal regulator of innate immune responses to bacterial infections, MIF appears to be a perfect target for novel therapeutic interventions in patients with severe sepsis...
  4. ncbi Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Infect Dis 187:S385-90. 2003
    ..Given its role in innate immune responses to bacterial infections, MIF is a novel target for therapeutic intervention in patients with septic shock...
  5. ncbi Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Eur J Immunol 37:3509-21. 2007
    ....
  6. ncbi Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4)
    Thierry Roger
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    J Endotoxin Res 9:119-23. 2003
    ..These findings identify an important role for MIF in innate immunity and provide a rationale for the development of anti-MIF strategy for the treatment of patients with Gram-negative septic shock...
  7. ncbi Role of MyD88 and Toll-like receptors 2 and 4 in the sensing of Parachlamydia acanthamoebae
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Infect Immun 78:5195-201. 2010
    ..Thus, in contrast to Chlamydia pneumoniae, Parachlamydia acanthamoebae weakly stimulates macrophages, potentially compensating for its low replication capacity in macrophages by escaping the innate immune surveillance...
  8. ncbi Macrophage migration inhibitory factor: a regulator of innate immunity
    Thierry Calandra
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Nat Rev Immunol 3:791-800. 2003
    ....
  9. ncbi Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection
    Thierry Roger
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, Lausanne, Switzerland
    Blood 117:1205-17. 2011
    ..Thus, these data identify an essential role for HDAC inhibitors in the regulation of the expression of innate immune genes and host defenses against microbial pathogens...
  10. ncbi Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection
    Julie Delaloye
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Cytokine 60:338-40. 2012
    ..Our results suggest that MIF is an integral component of the cytokine storm characteristic of AHI...
  11. ncbi Estradiol and progesterone strongly inhibit the innate immune response of mononuclear cells in newborns
    Eric Giannoni
    Service of Neonatology, Department of Pediatrics, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Infect Immun 79:2690-8. 2011
    ..Therefore, intrauterine exposure to estradiol and progesterone may participate in increasing susceptibility to infection during the neonatal period...
  12. ncbi Macrophage migration inhibitory factor: gene polymorphisms and susceptibility to inflammatory diseases
    Pascal Renner
    Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Infect Dis 41:S513-9. 2005
    ..Analyses of MIF genotypes in patients with sepsis may help to classify patients into risk categories and to identify those patients who may benefit from anti-MIF therapeutic strategies...
  13. ncbi Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoid-induced expression of mitogen-activated protein kinase phosphatase-1
    Thierry Roger
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Eur J Immunol 35:3405-13. 2005
    ..Taken together, these data identify MKP-1 as a molecular target of MIF-glucocorticoid crosstalk and provide a molecular basis for the control of macrophage responses by a pair of physiological regulators of innate immunity...
  14. ncbi A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease
    Pascal Renner
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    FASEB J 26:907-16. 2012
    ..09 and P=0.09 for MIF production). Taken together, these data suggest that polymorphisms of the MIF gene affecting MIF expression are associated with the occurrence, severity, and outcome of meningococcal disease in children...
  15. ncbi [New therapeutic strategies in severe sepsis and septic shock]
    Mauro Oddo
    Division des soins intensifs, Departement de Medecine, Interne CHUV, Lausanne
    Rev Med Suisse Romande 124:329-32. 2004
    ..This review will focus on these recently acquired therapeutic modalities, that are presently available to clinicians for the treatment of severe sepsis and septic shock...
  16. ncbi Changing face of health-care associated fungal infections
    Jacques Bille
    Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Curr Opin Infect Dis 18:314-9. 2005
    ..The purpose of this review was to evaluate recent publications on the epidemiology, diagnosis and management of invasive fungal infections...
  17. ncbi Macrophage migration inhibitory factor reduces the growth of virulent Mycobacterium tuberculosis in human macrophages
    Mauro Oddo
    Medical Critical Care Division, University Hospital, CH 1011 Lausanne, Switzerland
    Infect Immun 73:3783-6. 2005
    ..Its role in immunity to intracellular pathogens has not been well studied. Here, we show that MIF released by infected human macrophages inhibits the growth of virulent Mycobacterium tuberculosis...
  18. ncbi Clinical trials of antifungal prophylaxis among patients undergoing surgery
    Thierry Calandra
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Infect Dis 39:S185-92. 2004
    ..The aim is to maximize chances of reducing morbidity and mortality while minimizing treatment costs, exposure of low-risk patients to adverse events, and emergence of resistant fungal strains...
  19. ncbi Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000
    Oscar Marchetti
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Clin Infect Dis 38:311-20. 2004
    ..krusei remained rare (2%). Fluconazole consumption increased significantly (P<.001). Despite increasing high-risk activities, the incidence of candidemia remained unchanged, and no shift to resistant species occurred...
  20. ncbi Critical role for Ets, AP-1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression
    Thierry Roger
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, BH19 111, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Biochem J 387:355-65. 2005
    ..Yet, notable differences exist with respect to the elements implicated in gene regulation, which may account for species differences in terms of tissue expression and modulation by microbial and inflammatory stimuli...
  21. ncbi Cytokines in septic shock
    Thierry Calandra
    Division of Infectious Diseases, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Curr Clin Top Infect Dis 22:1-23. 2002
  22. ncbi The international sepsis forum consensus conference on definitions of infection in the intensive care unit
    Thierry Calandra
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    Crit Care Med 33:1538-48. 2005
    ..Use of these definitions in clinical trials should help improve the quality of clinical research in this field...
  23. ncbi Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
    Andres Pascual
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 46:201-11. 2008
    ..Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole metabolism. Large variations in voriconazole pharmacokinetics may be associated with decreased efficacy or with toxicity...
  24. ncbi 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia
    Laurence Senn
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 46:878-85. 2008
    ..The aim of the present prospective study was to evaluate the usefulness of monitoring BG in patients undergoing chemotherapy for acute leukemia...
  25. ncbi Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods
    Andres Pascual
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 51:137-43. 2007
    ..Simple HPLC and bioassay methods offer new tools for monitoring voriconazole therapy...
  26. ncbi Candida arteritis in patients who have not received organ transplants: case report and review of the literature
    Caroline Chapuis-Taillard
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    Clin Infect Dis 46:e106-11. 2008
    ..A high index of suspicion, early diagnosis, and prompt antifungal and surgical treatment seem crucial to efforts to avoid life-threatening arterial rupture and hemorrhage...
  27. ncbi Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections
    Andres Pascual
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Switzerland
    Clin Infect Dis 55:381-90. 2012
    ..Recommended oral voriconazole (VRC) doses are lower than intravenous doses. Because plasma concentrations impact efficacy and safety of therapy, optimizing individual drug exposure may improve these outcomes...
  28. ncbi Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease
    Alexandre Harari
    Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland
    Nat Med 17:372-6. 2011
    ..4%. Therefore, the proportion of single-positive TNF-α Mtb-specific CD4+ T cells is a new tool for the rapid diagnosis of active tuberculosis disease...
  29. ncbi Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome
    Julie Delaloye
    Department of Medicine, Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    PLoS Pathog 5:e1000480. 2009
    ..Delineation of the host response induced by MVA is critical for improving our understanding of poxvirus antiviral escape mechanisms and for designing new MVA vaccine vectors with improved immunogenicity...
  30. ncbi Monitoring procalcitonin in febrile neutropenia: what is its utility for initial diagnosis of infection and reassessment in persistent fever?
    James Owen Robinson
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne UNIL, Lausanne, Switzerland
    PLoS ONE 6:e18886. 2011
    ..We aimed at evaluating the utility of monitoring blood procalcitonin (PCT) in FE for initial diagnosis of infection and reassessment in persistent fever...
  31. ncbi Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies
    Maura Prella
    Infectious Diseases Service, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland
    Diagn Microbiol Infect Dis 51:95-101. 2005
    ..001). Candidiasis was diagnosed before neutrophil recovery in 78% and 11% of cases with Mn/anti-Mn and radiology, respectively (P < 0.001). Mn and anti-Mn may be useful for early noninvasive diagnosis of IC...
  32. ncbi Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species
    Laurence Senn
    Infectious Diseases Service, University Hospital, Lausanne, Switzerland
    BMC Infect Dis 6:9. 2006
    ..In this study, we reviewed the clinical manifestations of infections due to A. defectiva and Granulicatella species that occurred at our institution between 1998 and 2004...
  33. ncbi Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples
    Bertrand Rochat
    Quantitative Mass Spectrometry Facility, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    J Mass Spectrom 42:440-9. 2007
    ..Mean intra- and inter-day precision was 7.9 +/- 3.2% and 6.3 +/- 1.8%, respectively. This simple and robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method may easily be implemented for monitoring CASPO therapy...
  34. ncbi Infections in neutropenic cancer patients
    Oscar Marchetti
    Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    Lancet 359:723-5. 2002
  35. ncbi Histoplasma capsulatum var. duboisii infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing
    Cyril Pellaton
    Infectious Diseases Service, Centre Hospitalier Universitaire Vaudois, University of Lausanne, 1011 Lausanne, Switzerland
    Diagn Microbiol Infect Dis 64:85-9. 2009
    ..The variety duboisii of Hc was established using DNA sequencing of the polymorphic genomic region OLE. Molecular tools allow diagnosis of histoplasmosis in 24 h, which is drastically shorter than culture procedures...
  36. ncbi Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
    R Phillip Dellinger
    Cooper University Hospital, Camden, NJ, USA
    Crit Care Med 36:296-327. 2008
    ..To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004...
  37. ncbi Response to van Saene et al.'s comment on "Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients"
    Thierry Calandra
    Intensive Care Med 29:1196. 2003
  38. ncbi Antifungal prophylaxis for intensive care unit patients: let's fine tune it
    Thierry Calandra
    Intensive Care Med 28:1698-1700. 2002
  39. ncbi Treatment options of invasive fungal infections in adults
    Ursula Fluckiger
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland
    Swiss Med Wkly 136:447-63. 2006
    ..Amphotericin B deoxycholate is recommended as initial therapy for the empirical therapy in patients with neutropenia and persistent fever with close monitoring of adverse events...
  40. ncbi Pathogenesis of sepsis: new concepts and implications for future treatment
    Pierre-Yves Bochud
    Institute for Systems Biology, 1441 North 34th Street, Seattle, WA 98103-8904, USA
    BMJ 326:262-6. 2003
  41. ncbi Antimicrobial therapy for patients with severe sepsis and septic shock: an evidence-based review
    Pierre-Yves Bochud
    The Institute for Systems Biology, Seattle, WA, USA
    Crit Care Med 32:S495-512. 2004
    ..However, to minimize the promotion of antimicrobial resistance and cost and to maximize efficacy, detailed knowledge of the likely pathogens and the properties of the available drugs is necessary for the intensivist...
  42. ncbi Invasive candidiasis: comparison of management choices by infectious disease and critical care specialists
    Philippe Eggimann
    Infection Control Program, University of Geneva Hospitals, 24 rue Micheli-du-Crest, 1211, Geneva 14, Switzerland
    Intensive Care Med 31:1514-21. 2005
    ..1% vs. 51%). CONCLUSIONS: These data highlight differences between management approaches for candidiasis in two groups of specialists, particularly in the reported use of antifungals...
  43. ncbi Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor
    Timothy R D J Radstake
    Department of Rheumatology, Experimental Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Arthritis Rheum 52:3020-9. 2005
    ..To study whether genetic variants of macrophage migration inhibitory factor (MIF), the MIF -173G>C and CATT(5-8) alleles, are associated with disease severity and levels of circulating MIF in patients with rheumatoid arthritis (RA)...
  44. ncbi Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia
    Tom Sprong
    Department of General Internal Medicine, The Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands
    Shock 27:482-7. 2007
    ..Macrophage migration inhibitory factor cannot be detected in a human endotoxemia model and is not produced by whole blood cells incubated with LPS or meningococci...
  45. ncbi The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity
    Harry Flaster
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Mol Endocrinol 21:1267-80. 2007
    ..Therapeutic antagonism of MIF may be an effective approach for steroid-sparing therapies in patients with refractory autoimmune or inflammatory diseases...
  46. ncbi Sepsis: time to reconsider the concept
    Jean Carlet
    Intensive Care Unit, Infectious Diseases Department, Groupe Hospitalier Paris Saint Joseph, Paris, France
    Crit Care Med 36:964-6. 2008
    ..To discuss the difficulty in using the concept of sepsis for clinical trials and propose new ways for designing future trials for severe infections...
  47. ncbi Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease
    Hongqi Lue
    Laboratory of Biochemistry, Institute for Interfacial Engineering, University of Stuttgart, 70569 Stuttgart, Germany
    Microbes Infect 4:449-60. 2002
    ..Its mechanism of action is incompletely understood. Here, we attempt to correlate current knowledge on the molecular pathways of MIF activity with its functions in immunity and disease...
  48. ncbi Bench-to-bedside review: Candida infections in the intensive care unit
    Marie Méan
    Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
    Crit Care 12:204. 2008
    ..These include lipid formulations of amphotericin B, new azoles (voriconazole and posaconazole) and echinocandins (caspofungin, micafungin and anidulafungin)...
  49. ncbi A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer
    Murat Akova
    Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey
    Clin Infect Dis 40:239-45. 2005
    ..Neutropenic patients with cancer may develop several episodes of fever and infection during chemotherapy-induced myeloaplasia...
  50. ncbi Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C
    Ben de Pauw
    Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 46:1813-21. 2008
    ..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
  51. ncbi Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease
    Martijn Kwaijtaal
    Department of Medical Microbiology, University Hospital Maastricht, P Debeyeplein 25, P O Box 5800, 6202 AZ, Maastricht, The Netherlands
    Psychosom Med 69:68-73. 2007
    ..The first origin of MIF suggests positive, the second negative associations. The aim of this study was to explore the direction of the association of MIF with CAD and of MIF with exhaustion, if any...
  52. ncbi Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
    R Phillip Dellinger
    Crit Care Med 32:858-73. 2004
    ..The impact of these guidelines will be formally tested and guidelines updated annually and even more rapidly as some important new knowledge becomes as available...
  53. ncbi Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
    R Phillip Dellinger
    Section of Critical Care Medicine, Cooper University Hospital, One Cooper Plaza, 393 Dorrance, Camden, NJ 08103, USA
    Intensive Care Med 30:536-55. 2004
    ..The impact of these guidelines will be formally tested and guidelines updated annually, and even more rapidly when some important new knowledge becomes available...
  54. ncbi MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis
    Calin Popa
    Department of Rheumatology, Radboud University Nijmegen Medical Centre, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    Cytokine 36:51-6. 2006
    ..The secretion of MIF by dendritic cells is differentially regulated by TLRs. In addition, TNF-alpha, RANKL, and CD40L augment MIF production by DCs and thus play a potential role in the amplification of the inflammatory loop in RA...
  55. ncbi Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases
    Gibson S Kibiki
    Department of Internal Medicine, Endoscopy Unit, KCMC, Tumaini University, P O Box 3010, Moshi, Tanzania
    Clin Immunol 123:60-5. 2007
    ..In conclusion, HIV infection was associated with elevated serum MIF levels regardless of PTB. Low serum MIF levels were associated with high mortality...
  56. ncbi Outcome measures for clinical research in sepsis: a report of the 2nd Cambridge Colloquium of the International Sepsis Forum
    John C Marshall
    Department of Surgery, Interdepartmental Division of Critical Care Medicine, University of Toronto, St Michael s Hospital, Canada
    Crit Care Med 33:1708-16. 2005
    ..We sought to evaluate existing approaches and to draw on insights from other disciplines to propose a comprehensive approach to outcome evaluation in sepsis clinical trials...
  57. ncbi Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis
    Marieke Emonts
    Department of Pediatrics, Erasmus MC Sophia Children s Hospital University Medical Center, Rotterdam, The Netherlands
    Clin Infect Dis 44:1321-8. 2007
    ....
  58. ncbi Innate immunogenetics: a tool for exploring new frontiers of host defence
    Pierre Yves Bochud
    Institute for Systems Biology, Seattle, WA, USA
    Lancet Infect Dis 7:531-42. 2007
    ..This is likely to open new perspectives for the development of diagnostic, predictive, and preventive management strategies to combat infectious diseases...
  59. ncbi Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor
    Beatriz E Rendon
    Molecular Targets Program, J G Brown Cancer Center, University of Louisville, Louisville, Kentucky 40202, USA
    J Biol Chem 282:29910-8. 2007
    ....
  60. ncbi Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
    R Phillip Dellinger
    Cooper University Hospital, One Cooper Plaza, 393 Dorrance, Camden 08103, NJ, USA
    Intensive Care Med 34:17-60. 2008
    ..To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock," published in 2004...
  61. ncbi Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity
    Hongqi Lue
    Department of Biochemistry and Molecular Cell Biology, Institute of Biochemistry, University Hospital of the RWTH Aachen, Pauwelsstrasse 30, D 52074 Aachen, Germany
    Cell Signal 18:688-703. 2006
    ....